Abstract: The invention relates to the extraction of organic compounds from mixtures of said compounds with water, using a nanoporous carbon membrane. The invention can be used in any field where it is desired to separate an organic compound of interest from water, such as the drying of alcohols or alkanes.

Abstract: The present invention relates to vectors and compositions for the treatment of glycogen storage disease III.

Abstract: The invention relates to the use of interleukin-2 in treating Sjögren's syndrome in a subject, wherein IL-2 is to be administered at a low dose of less than about 3.5 MIU/day.

Abstract: Electroacoustic device that includes a body, an electrode to be electrically powered, named hot electrode, and an electrode to be electrically grounded, named ground electrode. The body includes a piezoelectric part or the electroacoustic device further including a piezoelectric part different from the body. The hot electrode includes a hot track spiraling around a spiral axis. The radial step between two consecutive coils of the hot track decreasing radially from the spiral axis. The hot electrode and the ground electrode are arranged on the piezoelectric part such as to define a wave transducer configured to generate a focalised ultrasonic vortex propagating in the body and/or, when a fluid medium is acoustically coupled with the electroacoustic device, in the fluid medium.

Abstract: A sol-gel method for producing an anti-corrosion coating consisting of at least one layer of an oxide on a metal substrate. A non-aqueous solution of a precursor of the oxide is prepared and deposited on one surface at least of the metal substrate in order to cover said surface at least partially with a film comprising the precursor of the oxide. Hydrolysis-condensation of the precursor of the oxide is carried out by exposing the film to a humid atmosphere in order to form an oxide network in the film. Then, a treatment for stabilizing the film on the surface of the substrate is carried out, followed by a heat treatment of the surface of the metal substrate in order to crystallize the network of oxide and form the anti-corrosion coating.

Abstract: In the present invention it is shown that the inactivation of the Pyk2 gene does not alter hippocampal development but prevents hippocampal-dependent memory tasks and LTP. Inventors clearly provide evidence for multiple roles of Pyk2 in spine morphology and postsynaptic structure. Thus, the inventors used direct overexpression of PYK2 by AAV-mediated gene transfer into the brain of Huntington's and Alzheimer's mouse models and found that overexpression of PYK2 in these 2 models improves synaptic properties and spine density deficits which is also accompanied by a rescue of spatial memory. Accordingly it was demonstrated that PYK2 may restore cognitive functions in neurodegenerative diseases. Thus the present invention relates to methods and pharmaceutical compositions for the treatment of neurodegenerative disease.

Abstract: The present invention relates to compounds and compositions comprising said compounds, for use in the prevention and/or treatment of non-alcoholic fatty liver disease (NAFLD), in particular hepatic steatosis or non-alcoholic steatohepatitis (NASH).

Abstract: A medical device for penetrating a bone structure including a processing unit having a transfer function that associates an electrical conductivity value S with a depth value d, wherein the processing unit is configured to detect a threshold selected from amongst an absolute threshold, a relative threshold and a critical gradient, and to emit a warning signal and/or control signal responsive to detection of the threshold.

Abstract: The invention relates to a method for determining the electrophoretic velocity of droplets of a first fluid in a second fluid, the method comprising: providing a first capillary (3?) having an outlet positioned in a first channel (3); providing a stream of the first fluid in the first capillary and providing a stream of the second fluid in the first channel external to the first capillary, so as to generate droplets of the first fluid in the second fluid at the outlet of the first capillary; transporting the droplets to an observation area (200) in a second channel (11); applying an electric field to the observation area of the second channel; and measuring the velocity of the droplets in the observation area. The invention also relates to a device for determining the electrophoretic velocity of droplets of a first fluid in a second fluid.

Abstract: The disclosure pertains to a compound of formula (I), one of its pharmaceutically acceptable salts, or a composition comprising thereof, for use in the prevention or treatment of glucose intolerance related conditions, insulin deficit related conditions, nonalcoholic fatty liver disease and/or obesity.

Abstract: A device for the storage and/or the editing of digital data including at least one double stranded, replicative, composite nucleic acid molecule. The composite nucleic acid molecule includes both digital data-encoding and non-digital data-encoding nucleic acids. The non-digital data-encoding nucleic acids may allow indexing and/or the provision of metadata for the flanking digital data-encoding nucleic acid. The composite nucleic acid molecules may be pooled to constitute an array and arrays may constitute a DNA drive, which represents the physical support on which the digital data are stored.

Abstract: Some embodiments include an electrolyte composition for a battery using sodium ions as electrochemical vector, to the use of such an electrolyte composition as non-aqueous liquid electrolyte in a sodium-ion battery and to a sodium-ion battery comprising such a non-aqueous liquid electrolyte. In some embodiments, the amount of (oxalato)borate ranges from 0.05 to 10 wt. %, relative to the total weight of the electrolyte composition.

Abstract: A method for generating an indicator or biomarker of colour perception in a mammalian subject, where the method may include submitting the mammalian subject to a multicoloured dynamic stimulus comprising displaying, on a display device. The method may include controlling a change over time of at least one of the two colours of the multicolour pattern when displaying the dynamic multicolour stimulus, to vary the displayed luminance of this colour (usually several times). The method may include acquiring, by using an image acquisition device, an oscillatory response of a pupil of the mammalian subject. The method may include generating, from the acquired response, a signal representative of the power of the pupil's oscillatory response as a function of the change over time of at least one of the two colours when displaying the dynamic multicoloured stimulus.

Abstract: The invention relates to a method for acquiring an image by an imager (20) comprising a matrix of pixels configured to generate an electric response when exposed to an incident light flux travelling through an optical path (21) in which is arranged a wavefront correction element (22), comprising the following steps: 1) initiating the exposure of the pixels to the incident light flux; 2) for a plurality of iterations during the exposure: 2.1) non-destructive reading of the electric responses of pixels of a region of interest; 2.2) determining an evolution of the spatial distribution of pixels in logarithmic mode previous iteration with respect to the previous iteration; 2.3) based on said evolution, establishing a command for the wavefront correction element (22) in order to correct the wavefront; 2.4) configuring the wavefront correction element, 3) reading the electric responses of the pixels resulting in an image.

Abstract: Adeno-associated virus (AAV) is a defective mono-stranded DNA virus, endemic in human population (35-80%). Recurrent clonal AAV2 insertions are associated with the pathogenesis of rare human hepatocellular carcinoma (HCC) developed on normal liver. The aimed of the inventors was to characterize the natural history of AAV infection in the liver. Viral DNA was thus quantified in tumor and non-tumor liver tissues of 1461 patients. Presence of episomal form and viral mRNA expression were analyzed using a DNAse/TaqMan based assay and quantitative RT-PCR. In silico analyses using viral capture data explored viral variants and new clonal insertions. AAV DNA was detected in 21% of the patients equally distributed in 2 major viral subtypes: one similar to AAV2, the other hybrid between AAV2 and AAV13 sequences. Thus the inventors provided an integrated analysis of the wild type AAV infection in the liver with the identification of viral genotypes, molecular forms, helper virus relationship and viral integrations.

Abstract: The present invention relates to conjugates formed from a cell-penetrating peptide carrier linked to a therapeutic molecule, wherein the peptide carrier is defined by specific domains and the therapeutic molecule is a nucleic acid formed of trinucleotide repeats. The present invention further relates to the use of such a conjugate in methods of treatment or as a medicament, especially in the treatment of trinucleotide repeat disorders such as myotonic dystrophy (DM1).

Abstract: A method for providing cardioprotection in a subject who experienced a myocardial infarction, including administering a therapeutically effective amount of a Granzyme B inhibitor. Following acute MI in mice, CD8+ T lymphocytes are quickly recruited and activated in ischemic heart tissue, and release Granzyme B, leading to cardiomyocyte apoptosis and deterioration of myocardial function. Antibody-mediated depletion of CD8+ T lymphocytes decreases Granzyme B content and apoptotic within the myocardium and inflammatory response. mAb mediated-CD8 depletion limits myocardial injury and improves heart function. These effects are recapitulated in mice with CD8+ T cell selective Granzyme B deficiency in mice. Granzyme B is produced by other cell types (e.g., NK cells). Global Granzyme B deletion (GzmB-/- mice) decreases apoptotic within the myocardium, reduces local pro-inflammatory signature and ultimately limits infarct size after MI.

Abstract: The present invention relates to variants of acid-alpha glucosidase and uses thereof. Said variants are sequence-optimized and/or are linked to a heterogenous signal peptide.

Abstract: An implantable ultrasound generating treating device (12) to induce spinal cord or spinal nerves treatment, suitable for implantation in the spinal canal and comprises an elongate support member (22, 32) and an array of several treatment transducers (20) distributed along the elongate support member. The several treatment transducers (20) comprise radial transducers emitting an ultrasound treatment beam oriented radially, wherein the treatment transducers (20) have a resonant frequency comprised between 0.5 and 4 MHz. The device has articulating portions so that the implantable device can adapt its shape to a curved elongation path. Also disclosed is an apparatus including the implantable ultrasound generating treating device and methods comprising inserting the implantable ultrasound generating treating device (12) inside the spinal canal of the spine of the patient.

Abstract: Recombinant, alive and metabolically active bacteria including a heterologous prokaryotic biomineralized ferritin. In particular, the inventors have shown that naturally non-magnetic Escherichia coli may be engineered to become magnetic by the expression and the biomineralization of the ferritin of Pyrococcus furiosus. Moreover, the inventors have shown that a fixed number of magnetic E. coli strains keep their magnetic properties through cell division by asymmetrical division. The inventors have also shown that magnetic bacteria according to the invention may be of use in both non-therapeutic and therapeutic uses, such as, e.g., the biosensing of target substance, the depollution of complex environments, the display of antibodies, nanobodies and antigens, the delivery of therapeutic substance to target cells, the targeting and infection of target cells.